GL1X · GenesisL1 explorer

MolNFT v1 · #164742 · protein

Human plasmakallikrein protease domain in complex with active site directed inhibitor

6T7P · Plasma kallikrein: “Human plasmakallikrein protease domain in complex with active site directed inhibitor”. X-ray diffraction, 3 ligands (GSH, MU8, PO4), 3 pockets (best druggability 0.46). MolNFT v1 #164742 on GenesisL1: 3D…

PDB
6T7P
Type
protein
Length
237 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Plasma kallikrein
EC
3.4.21.34
UniProt
P03952
Ligands
GSH, MU8, PO4
Pockets
3 · best druggability 0.46

Structure

x-ray diffraction · 1 distinct chain · 12% helix, 35% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
APlasma kallikrein (EC 3.4.21.34)protein23712% helix, 35% strandP03952

Ligands and binding sites

  • GSH · Glutathione · ligand · chains A
  • MU8 · (2~{S},4~{R})-1-[[(3~{S})-3-azanyl-2,3-dihydro-1-benzofuran-6-yl]carbonyl]-~{N}-(3-chlorophenyl)-4-phenyl-pyrrolidine-2-carboxamide · ligand · chains A
  • PO4 · Phosphate ion · ion · chains A
  • DMS · Dimethyl sulfoxide · additive · 10 copies · chains A
  • GOL · Glycerol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11320.460.7834MU8
2550.420.8214empty
3820.360.7523DMS

Modifications

Observed in the structure: 4 disulfide, 1 covalent (disulfide, covalent ligand).

Compared structures

  • 6T7P · human plasmakallikrein protease domain in complex with active site directed inhibitor · the same entry in another collection · chain A against A, TM-score 1.00
  • P03952 · AlphaFold monomer V2.0 prediction for plasma kallikrein (P03952) · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.